Table 2.

Frequencies of adverse events of MS patients treated with cannabinoids from studies where frequencies were reported.

Adverse Event	[69]	[70]	[71]	[72]	[73]	[74]	[75]	[76]	Total
Dizziness	5	7	13	35	4	34	50	4	152
Headache	0	0	9	0	0	7	9	3	208
Somnolence	0	0	9	11	0	16	0	0	36
Muscle Weakness	3	2	5	0	0	1	0	3	14
Spasticity	0	0	3	4	0	0	0	0	7
Paraesthesia	0	0	2	0	0	0	0	0	2
Tremor	0	0	3	0	0	0	0	1	4
Vertigo	2	1	0	0	0	16	34	4	57
Tinnitus	0	0	2	0	0	0	0	0	2
Mood Disruption	0	0	0	0	0	2	0	1	3
Euphoria	0	0	9	0	0	0	0	1	10
Attention	0	0	1	0	2	6	0	11	20
Insomnia	0	0	1	0	0	0	2	0	3
Fatigue	5	0	5	29	2	16	25	6	88
Feeling abnormal	0	0	5	50	0	5	0	0	60
Feeling hot	0	0	3	0	0	0	0	0	3
Oral Discomfort	4	0	3	0	0	19	13	5	44
Nausea	2	0	1	0	0	12	17	2	34
Appetite	0	0	2	3	0	0	0	0	5
Stomatitis	1	0	0	0	0	0	0	0	1
Incontinence	1	0	0	0	0	0	0	0	1
Hypertension	0	1	0	0	0	8	0	0	9
Pharyngodynia	0	1	0	0	0	2	0	0	3
Vision Blurred	0	0	0	0	0	4	0	0	4
Diarrhoea	0	0	0	0	0	7	13	0	20
Vomiting	0	0	0	0	0	5	0	0	5
Memory Impairment	0	0	0	0	0	6	0	0	6
Psychomotor Impairment	0	0	0	0	0	5	0	0	5
Total Adverse Events									806
Total Participants	166	22	24	144	28	312	333	17